The Patent Finder

InflaRx GmbH

15 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Nov 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 7, 2027
    The maintenance fee for ANTI-C5A Binding Moieties with High Blocking Activity (US 9,073,983) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
  • 1 fee due Feb 13, 2027
    The maintenance fee for Treatment of inflammatory diseases with inhibitors of C5a activity (US 10,376,595) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 1 fee due Aug 6, 2027
    The maintenance fee for Treatment of inflammatory diseases with inhibitors of C5A activity (US 11,890,349) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,802,096ANTI-C5A Binding Antibodies with High Block Activity
In force
 · High confidence
In forceHigh confidence
US 9,073,983ANTI-C5A Binding Moieties with High Blocking Activity
In force
 · High confidence
In forceHigh confidence
US 9,458,233ANTI-C5A Binding Moieties with High Blocking Activity
In force
 · High confidence
In forceHigh confidence
US 10,774,136Anti-C5a Binding Moieties With High Blocking Activity
In force
 · High confidence
In forceHigh confidence
US 10,227,397Inhibitors of C5A for the Treatment of Viral Pneumonia
In force
 · High confidence
In forceHigh confidence
US 10,858,421Inhibitors of C5A for the treatment of viral pneumonia
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,376,595Treatment of inflammatory diseases with inhibitors of C5a activity
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,464,868Treatment of inflammatory diseases with inhibitors of C5A activity
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,890,349Treatment of inflammatory diseases with inhibitors of C5A activity
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,273,225Treatment of inflammatory diseases with inhibitors of C5a activity
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited